Stefan Wohlfeil
Director/Board Member at Actimed Therapeutics Ltd.
Profile
Stefan Wohlfeil is the founder of Atani Ltd.
He is currently a Non-Executive Director at Actimed Therapeutics Ltd.
and a Director at TXP Pharma AG (Switzerland).
Previously, he was the Chief Executive Officer & Managing Director at TRIN Pharma GmbH, a Director at Opterion Health AG, the Chief Medical Officer at Vifor Pharma AG, a Vice President at Bayer Pharma Chemicals Co., the Chief Medical Officer and Head-Research & Development at Vifor Pharma Management AG, and the Head-Chemical & Preclinical Research at OM Pharma SA.
Stefan Wohlfeil active positions
Companies | Position | Start |
---|---|---|
Actimed Therapeutics Ltd.
Actimed Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education. | Director/Board Member | 30/04/2019 |
TXP Pharma AG (Switzerland)
TXP Pharma AG (Switzerland) Pharmaceuticals: MajorHealth Technology Part of SynAct Pharma AB, TXP Pharma AG (Switzerland) engages in researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. The private company is based in Baar, Switzerland. TXP Pharma AG (Switzerland was acquired by SynAct Pharma AB from GoodWind Holding GmbH on January 16, 2023 for $264.94 million. | Director/Board Member | - |
Former positions of Stefan Wohlfeil
Companies | Position | End |
---|---|---|
Vifor Pharma Management AG
Vifor Pharma Management AG Pharmaceuticals: MajorHealth Technology Vifor Pharma Management AG develops and manufactures pharmaceuticals products for the treatment of iron deficiency. It also offers a diversified portfolio of prescription medicines as well as over-the-counter products. The company operates in the following key business areas: iron deficiency with and without anemia, kidney disease, infectious diseases/OTX products and consumer healthcare, with a focus on non-prescription products. Vifor Pharma Management was founded by Caspar Friedrich Hausmann in 1872 and is headquartered in Glattbrugg, Switzerland. | Chief Tech/Sci/R&D Officer | 31/12/2018 |
TRIN Pharma GmbH
TRIN Pharma GmbH Medical/Nursing ServicesHealth Services TRIN Pharma GmbH develops new small molecule drugs for an effective tumor treatment. Its research is focused on innovative compounds with a proprietary molecular structure, with high selectivity and potent anti-tumor activity. TRIN Pharma's business objective is the development of its molecules into clinical studies and commercialization. | President | 22/05/2011 |
Opterion Health AG
Opterion Health AG Medical/Nursing ServicesHealth Services Opterion Health AG is a Swiss company that focuses on bringing innovation to dialysis care and fostering home dialysis to improve the quality of life for patients suffering from end-stage renal disease (ESRD). Opterion Health is based in Muttenz, CH. The private company aims to increase the survival rates of people with ESRD and reduce healthcare costs. The company was founded in 2012 by Guido Grentzmann, and the CEO is Bjorn Englund. | Director/Board Member | - |
OM Pharma SA
OM Pharma SA Pharmaceuticals: MajorHealth Technology OM Pharma SA engages in manufacture of pharmaceutical products. Its portfolio includes products for respiratory tract infections, lower urinary tract infections, chronic venous insufficiency, microangiopathies, hemorrhoids, and menometrorrhagia. The company was founded by Jean-Rene Ricard in 1937 and is headquartered in Meyrin, Switzerland. | Corporate Officer/Principal | - |
VIFOR PHARMA | Chief Tech/Sci/R&D Officer | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 9 |
---|---|
Vifor Pharma AG
Vifor Pharma AG Pharmaceuticals: MajorHealth Technology Vifor Pharma AG is a pharmaceutical company, which engages in the research, development, production, and marketing of therapeutic products. It operates through the following geographical segments: Switzerland, Europe, USA, Rest of World, and Group. The firm offers products for iron deficiency, nephrology, and cardio-renal therapies. It specializes in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision patient care. The company was founded in 1927 and is headquartered in St. Gallen, Switzerland. | Health Technology |
Bayer Pharma Chemicals Co. | |
TRIN Pharma GmbH
TRIN Pharma GmbH Medical/Nursing ServicesHealth Services TRIN Pharma GmbH develops new small molecule drugs for an effective tumor treatment. Its research is focused on innovative compounds with a proprietary molecular structure, with high selectivity and potent anti-tumor activity. TRIN Pharma's business objective is the development of its molecules into clinical studies and commercialization. | Health Services |
Atani Ltd.
Atani Ltd. Pharmaceuticals: GenericHealth Technology Atani Ltd. manufactures and markets drugs. The firm's drugs are used for the treatment of cancer. The company was founded by Stefan Wohlfeil and is headquartered in Tokyo, Japan | Health Technology |
Vifor Pharma Management AG
Vifor Pharma Management AG Pharmaceuticals: MajorHealth Technology Vifor Pharma Management AG develops and manufactures pharmaceuticals products for the treatment of iron deficiency. It also offers a diversified portfolio of prescription medicines as well as over-the-counter products. The company operates in the following key business areas: iron deficiency with and without anemia, kidney disease, infectious diseases/OTX products and consumer healthcare, with a focus on non-prescription products. Vifor Pharma Management was founded by Caspar Friedrich Hausmann in 1872 and is headquartered in Glattbrugg, Switzerland. | Health Technology |
OM Pharma SA
OM Pharma SA Pharmaceuticals: MajorHealth Technology OM Pharma SA engages in manufacture of pharmaceutical products. Its portfolio includes products for respiratory tract infections, lower urinary tract infections, chronic venous insufficiency, microangiopathies, hemorrhoids, and menometrorrhagia. The company was founded by Jean-Rene Ricard in 1937 and is headquartered in Meyrin, Switzerland. | Health Technology |
Opterion Health AG
Opterion Health AG Medical/Nursing ServicesHealth Services Opterion Health AG is a Swiss company that focuses on bringing innovation to dialysis care and fostering home dialysis to improve the quality of life for patients suffering from end-stage renal disease (ESRD). Opterion Health is based in Muttenz, CH. The private company aims to increase the survival rates of people with ESRD and reduce healthcare costs. The company was founded in 2012 by Guido Grentzmann, and the CEO is Bjorn Englund. | Health Services |
Actimed Therapeutics Ltd.
Actimed Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education. | Commercial Services |
TXP Pharma AG (Switzerland)
TXP Pharma AG (Switzerland) Pharmaceuticals: MajorHealth Technology Part of SynAct Pharma AB, TXP Pharma AG (Switzerland) engages in researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. The private company is based in Baar, Switzerland. TXP Pharma AG (Switzerland was acquired by SynAct Pharma AB from GoodWind Holding GmbH on January 16, 2023 for $264.94 million. | Health Technology |
- Stock Market
- Insiders
- Stefan Wohlfeil